Patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) will have subsidised access to dasatinib (Sprycel) from August 1. Newly diagnosed adult patients (aged 18 years and over) Ph+ ALL will be eligible for PBS subsidised treatment with the TKI as a first line oral therapy, when this is integrated with chemotherapy. Professor Andrew Grigg, Director of Clinical Haematology ...
Second TKI listed on PBS for adults with Ph+ALL
By Michael Woodhead
1 Aug 2019